- Home
- LICN vs SHPH Comparison
LICN vs SHPH Comparison
Compare LICN & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LICN
- SHPH
- Stock Information
- Founded
- LICN 2004
- SHPH 2012
- Country
- LICN China
- SHPH United States
- Employees
- LICN N/A
- SHPH N/A
- Industry
- LICN
- SHPH Biotechnology: Pharmaceutical Preparations
- Sector
- LICN
- SHPH Health Care
- Exchange
- LICN Nasdaq
- SHPH Nasdaq
- Market Cap
- LICN 2.1M
- SHPH 2.3M
- IPO Year
- LICN 2023
- SHPH 2022
- Fundamental
- Price
- LICN $4.92
- SHPH $0.17
- Analyst Decision
- LICN
- SHPH
- Analyst Count
- LICN 0
- SHPH 0
- Target Price
- LICN N/A
- SHPH N/A
- AVG Volume (30 Days)
- LICN 1.7M
- SHPH 12.3M
- Earning Date
- LICN 01-01-0001
- SHPH 05-08-2025
- Dividend Yield
- LICN N/A
- SHPH N/A
- EPS Growth
- LICN N/A
- SHPH N/A
- EPS
- LICN N/A
- SHPH N/A
- Revenue
- LICN $41,477,000.00
- SHPH N/A
- Revenue This Year
- LICN N/A
- SHPH N/A
- Revenue Next Year
- LICN N/A
- SHPH N/A
- P/E Ratio
- LICN N/A
- SHPH N/A
- Revenue Growth
- LICN 4.32
- SHPH N/A
- 52 Week Low
- LICN $2.60
- SHPH $0.16
- 52 Week High
- LICN $488.00
- SHPH $4.71
- Technical
- Relative Strength Index (RSI)
- LICN 49.93
- SHPH 30.47
- Support Level
- LICN $5.61
- SHPH $0.16
- Resistance Level
- LICN $6.16
- SHPH $0.18
- Average True Range (ATR)
- LICN 1.10
- SHPH 0.02
- MACD
- LICN -0.11
- SHPH 0.00
- Stochastic Oscillator
- LICN 40.85
- SHPH 10.19
About LICN Lichen China Limited
Lichen International Ltd formerly Lichen China Ltd is a holding company. The company, along with its subsidiaries provides financial and taxation solution services; education support services; and software and maintenance services. The company generates Majority revenue from Financial and taxation solution services.
About SHPH Shuttle Pharmaceuticals Holdings Inc.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.